Agenus Inc. (NASDAQ:AGEN - Get Free Report) has been given an average recommendation of "Hold" by the six ratings firms that are covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $14.00.
AGEN has been the subject of several research analyst reports. B. Riley reiterated a "buy" rating on shares of Agenus in a research report on Monday, April 21st. Wall Street Zen upgraded Agenus from a "strong sell" rating to a "hold" rating in a research report on Thursday, May 22nd. HC Wainwright upgraded Agenus from a "neutral" rating to a "buy" rating and set a $25.00 target price for the company in a research report on Wednesday, June 4th. Finally, Robert W. Baird increased their price target on Agenus from $4.00 to $6.00 and gave the company a "neutral" rating in a research note on Wednesday, June 4th.
Check Out Our Latest Research Report on Agenus
Agenus Stock Down 14.7%
AGEN traded down $0.89 during midday trading on Friday, reaching $5.18. The company had a trading volume of 2,131,384 shares, compared to its average volume of 695,860. The business has a 50-day moving average of $4.23 and a two-hundred day moving average of $3.22. The company has a market cap of $142.04 million, a P/E ratio of -0.60 and a beta of 1.51. Agenus has a 1 year low of $1.38 and a 1 year high of $18.74.
Agenus (NASDAQ:AGEN - Get Free Report) last released its earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $0.58. The business had revenue of $24.07 million for the quarter, compared to analysts' expectations of $26.38 million. On average, equities research analysts predict that Agenus will post -12.55 EPS for the current year.
Hedge Funds Weigh In On Agenus
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Corton Capital Inc. purchased a new position in Agenus during the 4th quarter worth $36,000. Apollon Wealth Management LLC raised its position in shares of Agenus by 25.0% in the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company's stock worth $38,000 after acquiring an additional 5,000 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Agenus in the 4th quarter worth $51,000. Acadian Asset Management LLC bought a new position in shares of Agenus in the 1st quarter worth $58,000. Finally, Bank of Montreal Can bought a new position in shares of Agenus in the 4th quarter worth $69,000. 61.46% of the stock is owned by institutional investors.
Agenus Company Profile
(
Get Free ReportAgenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
See Also
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
